基本信息:
- 专利标题： T Cell Modification and Use Thereof
- 申请号：US17468225 申请日：2021-09-07
- 公开(公告)号：US20220064305A1 公开(公告)日：2022-03-03
- 发明人： Garth Hamilton , Jonathan Silk , Claire Gueguen
- 申请人： ADAPTIMMUNE LIMITED
- 申请人地址： GB OXFORDSHIRE
- 专利权人： ADAPTIMMUNE LIMITED
- 当前专利权人： ADAPTIMMUNE LIMITED
- 当前专利权人地址： GB OXFORDSHIRE
- 优先权： GB1713078.2 20170815
- 主分类号： C07K16/28
- IPC分类号： C07K16/28 ; A61P35/00 ; C07K14/725 ; C07K14/47 ; A61K39/00 ; C07K16/30 ; C07K14/54 ; C07K16/24 ; C12N5/0783
摘要：
This invention relates to modified T cells that inducibly express a bioactive molecule, such as IL-7, and constitutively expresses an antigen receptor, such as a T cell receptor or chimeric antigen receptor that binds to a tumour antigen. The modified T cells may comprise a nucleic acid construct that comprises a first nucleotide sequence encoding the bioactive molecule, a second nucleotide sequence encoding the antigen receptor; an inducible promoter operably linked to the first nucleotide sequence and a constitutive promoter operably linked to the second nucleotide. Nucleic acid constructs and vectors are provided, as well as T cells comprising such constructs and vectors and therapeutic methods and uses thereof.
公开/授权文献:
- US12145990B2 T cell modification and use thereof 公开/授权日：2024-11-19
IPC结构图谱:
| C | 化学；冶金 |
| --C07 | 有机化学 |
| ----C07K | 肽 |
| ------C07K16/00 | 免疫球蛋白，例如，单克隆或多克隆抗体 |
| --------C07K16/18 | .来自动物或人的抵抗物质 |
| ----------C07K16/28 | ..抗受体，细胞表面抗原或细胞表面决定因子 |